Report overview
Nonalcoholic steatohepatitis (NASH) is?inflammation of your liver caused by excess fat cells in it (fatty liver disease). Chronic inflammation causes progressive liver damage. NASH resembles hepatitis caused by alcohol use, but it stems from something else.
This report contains market size and forecasts of Non-Alcoholic Steatohepatitis Treatment in Global, including the following market information:
Global Non-Alcoholic Steatohepatitis Treatment Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Non-Alcoholic Steatohepatitis Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Vitamin E and Pioglitazone Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Non-Alcoholic Steatohepatitis Treatment include Intercept Pharmaceuticals, Galmed Pharmaceuticals, Inventiva Pharma, AbbVie Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals, NGM Biopharmaceuticals Inc., Novo Nordisk A/S and Bristol Myers Squibb, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-Alcoholic Steatohepatitis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Alcoholic Steatohepatitis Treatment Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis Treatment Market Segment Percentages, by Type, 2022 (%)
Vitamin E and Pioglitazone
Obeticholic Acid (OCA)
Lanifibranor
Semaglutide
Resmetirom
Aramchol
Cenicriviroc
Others
Global Non-Alcoholic Steatohepatitis Treatment Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail & Specialty Pharmacies
Others
Global Non-Alcoholic Steatohepatitis Treatment Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Non-Alcoholic Steatohepatitis Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Alcoholic Steatohepatitis Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Alcoholic Steatohepatitis Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Intercept Pharmaceuticals
Galmed Pharmaceuticals
Inventiva Pharma
AbbVie Inc.
Galectin Therapeutics Inc.
Madrigal Pharmaceuticals
NGM Biopharmaceuticals Inc.
Novo Nordisk A/S
Bristol Myers Squibb
Gilead Sciences Inc.
